Manufacturing

Many life-sciences companies are likely to execute an acquisition in the next 12-24 months, according to a survey by Ernst & Young.

Influenza vaccines can be produced faster using a new insect cell-based technology compared with traditional egg-based processes, according to scientists in Vienna (Austria).

Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for a H1N1 vaccine.

On Jan. 4, 2010, Novartis (Basel) and Nestlé began completing their 2008 agreement, under which Novartis will acquire Nestlé's remaining 52% stake in eye-care company Alcon (Hünenberg, Switzerland).

Bioject Medical Technologies establishes alliance with MPI Research; Biogen Idec CEO to retire; And More.

Microelectronics offers "striking opportunities" for advancing biomedical research and creating new markets for the medical sciences industry.

This study used biological indicators containing Geobacillus stearothermophilus spores and a new technology to continuously monitor incubated BIs and record nonsterile results.

A comprehensive book about mass transfer benefits from the author's personal touch.

Team leaders in FDA's Office of Generic Drugs provide an overview.

Plus, novel dosage forms and emerging trends.

The authors describe the implementation of an on-line particle-size analyzer on an active pharmaceutical ingredient milling operation at a commercial site.

From healthcare to corruption to life expectancy, here's what we can learn from the past decade.

Directors and staff miss the mark when it comes to following procedures.

There is a pressing need to improve the storage stability of currently available vaccines, and achieving this could facilitate mass vaccination campaigns and increase vaccination coverage on a global scale — particularly to underserved and remote regions of the world.

BioNanomatrix (Philadelphia) names Edward Erickson president and CEO; and More.

Hospira, a specialty pharmaceutical company, has agreed to acquire Orchid Chemicals' Pharmaceuticals for $400 million.

Merck & Co. Acquires Avecia Biologics; Ambrilia Biopharma Closes Manufacturing Facility; And More.

Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO).

The European Public Health Alliance published its comments about the Falsified Medicines Directive currently under debate by the European Parliament and Council.

Mergers and acquisitions will contribute almost two-thirds of peer-set sales growth until 2014, according to market analyst Datamonitor.

Eli Lilly outlined its growth strategy at its annual meeting with the investment community last week.

Also, Abbott to acquire Starlims Technologies; GSK Biologicals to form alliance with Intercell.

PharmTech's monthly newsletter, Equipment & Processing Report, reviews the Editor's Picks for the December 2009 edition from Sepha and AdvantaPure.

Company and People Notes: Also, Pfizer and Protalix enter agreement; Watson acquires Arrow Group; and more.

The US Congressional Budget Office released a report that analyzes the pharmaceutical industry?s advertising strategies.

Personalized medicine has been described by analysts PricewaterhouseCoopers as a "disruptive influence" that will create both opportunities and challenges for traditional healthcare.

What makes a new sterile plant award winning?

The private industry has been urged to join a public sector commitment fund in the UK to advance manufacturing R&D in bioprocessing, following the investment of approximately £9 million from two UK research councils.

sanofi-aventis (Paris) announced last week that it has signed a memorandum of understanding (MoU)with Prominvest.

Novartis officially inaugurated its large-scale flu cell-culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina.